Search

Your search keyword '"Gaglione, Erika"' showing total 46 results
Start Over Author "Gaglione, Erika"
46 results on '"Gaglione, Erika"'

1. Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

Author

Baskar, Sivasubramanian, Peng, Haiyong, Gaglione, Erika M., Carstens, Elizabeth J., Lindorfer, Margaret A., Ahn, Inhye E., Herman, Sarah E. M., Skarzynski, Martin, Chang, Jing, Keyvanfar, Keyvan, Butera, Vicent, Blackburn, Amy, Vire, Bérengère, Maric, Irina, Stetler-Stevenson, Maryalice, Yuan, Constance M., Eckhaus, Michael A., Soto, Susan, Farooqui, Mohammed Z. H., Taylor, Ronald P., Rader, Christoph, and Wiestner, Adrian

Published
2025
Full Text
View/download PDF

3. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Author

Zhang, Deyi, Harris, Hailey M., Chen, Jonathan, Judy, Jen, James, Gabriella, Kelly, Aileen, McIntosh, Joel, Tenn-McClellan, Austin, Ambing, Eileen, Tan, Ying Siow, Lu, Hao, Gajewski, Stefan, Clifton, Matthew C., Yung, Stephanie, Robbins, Daniel W., Pirooznia, Mehdi, Skånland, Sigrid S., Gaglione, Erika, Mhibik, Maissa, Underbayev, Chingiz, Ahn, Inhye E., Sun, Clare, Herman, Sarah E. M., Noviski, Mark, and Wiestner, Adrian

Published
2023
Full Text
View/download PDF

5. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Author

Sun, Clare, Nierman, Pia, Kendall, Ellen K., Cheung, Jean, Gulrajani, Michael, Herman, Sarah E.M., Pleyer, Christopher, Ahn, Inhye E., Stetler-Stevenson, Maryalice, Yuan, Constance M., Maric, Irina, Gaglione, Erika M., Harris, Hailey M., Pittaluga, Stefania, Wang, Min Hui, Patel, Priti, Farooqui, Mohammed Z.H., Izumi, Raquel, Hamdy, Ahmed, Covey, Todd, and Wiestner, Adrian

Published
2020
Full Text
View/download PDF

6. Fig S3 from Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Author

Alsadhan, Anfal, primary, Cheung, Jean, primary, Gulrajani, Michael, primary, Gaglione, Erika M., primary, Nierman, Pia, primary, Hamdy, Ahmed, primary, Izumi, Raquel, primary, Bibikova, Elena, primary, Patel, Priti, primary, Sun, Clare, primary, Covey, Todd, primary, Herman, Sarah E.M., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Methods S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

10. Data from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Author

Alsadhan, Anfal, primary, Chen, Jonathan, primary, Gaglione, Erika M., primary, Underbayev, Chingiz, primary, Tuma, Pamela L., primary, Tian, Xin, primary, Freeman, Lita A., primary, Baskar, Sivasubramanian, primary, Nierman, Pia, primary, Soto, Susan, primary, Itsara, Andy, primary, Ahn, Inhye E., primary, Sun, Clare, primary, Bibikova, Elena, primary, Hartmann, Tanja Nicole, primary, Mhibik, Maissa, primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

11. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.

Author

Alsadhan, Anfal, primary, Chen, Jonathan, additional, Gaglione, Erika M., additional, Underbayev, Chingiz, additional, Tuma, Pamela L., additional, Tian, Xin, additional, Freeman, Lita A., additional, Baskar, Sivasubramanian, additional, Nierman, Pia, additional, Soto, Susan, additional, Itsara, Andy, additional, Ahn, Inhye E., additional, Sun, Clare, additional, Bibikova, Elena, additional, Hartmann, Tanja Nicole., additional, Mhibik, Maissa, additional, and Wiestner, Adrian, additional

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 5 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

14. Oligos and Primers - related to Methods from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

15. Data from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 1 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 6 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 7 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Methods from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures and Legends from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 4 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 3 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., primary, Wang, James Q., primary, Huang, DaWei, primary, Wright, George W., primary, Kasbekar, Monica, primary, Choi, Jaewoo, primary, Young, Ryan M., primary, Webster, Daniel E., primary, Yang, Yandan, primary, Zhao, Hong, primary, Yu, Xin, primary, Xu, Weihong, primary, Roulland, Sandrine, primary, Ceribelli, Michele, primary, Zhang, Xiaohu, primary, Wilson, Kelli M., primary, Chen, Lu, primary, McKnight, Crystal, primary, Klumpp-Thomas, Carleen, primary, Thomas, Craig J., primary, Häupl, Björn, primary, Oellerich, Thomas, primary, Rae, Zachary, primary, Kelly, Michael C., primary, Ahn, Inhye E., primary, Sun, Clare, primary, Gaglione, Erika M., primary, Wilson, Wyndham H., primary, Wiestner, Adrian, primary, and Staudt, Louis M., primary

Published
2023
Full Text
View/download PDF

30. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

Author

Cyr, Matthew G, primary, Mhibik, Maissa, additional, Qi, Junpeng, additional, Peng, Haiyong, additional, Chang, Jing, additional, Gaglione, Erika M, additional, Eik, David, additional, Herrick, John, additional, Venables, Thomas, additional, Novick, Scott J, additional, Courouble, Valentine V, additional, Griffin, Patrick R, additional, Wiestner, Adrian, additional, and Rader, Christoph, additional

Published
2022
Full Text
View/download PDF

32. Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Author

Pleyer, Christopher, primary, Laing, Kerry J, additional, Ali, Mir, additional, McClurkan, Christopher L, additional, Soto, Susan, additional, Ahn, Inhye E., additional, Nierman, Pia, additional, Maddux, Emeline, additional, Lotter, Jennifer, additional, Superata, Jeanine, additional, Tian, Xin, additional, Gaglione, Erika M, additional, Wiestner, Adrian, additional, Cohen, Jeffrey, additional, Koelle, David M, additional, and Sun, Clare, additional

Published
2021
Full Text
View/download PDF

34. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Author

Shaffer, Arthur L., primary, Phelan, James D., additional, Wang, James Q., additional, Huang, DaWei, additional, Wright, George W., additional, Kasbekar, Monica, additional, Choi, Jaewoo, additional, Young, Ryan M., additional, Webster, Daniel E., additional, Yang, Yandan, additional, Zhao, Hong, additional, Yu, Xin, additional, Xu, Weihong, additional, Roulland, Sandrine, additional, Ceribelli, Michele, additional, Zhang, Xiaohu, additional, Wilson, Kelli M., additional, Chen, Lu, additional, McKnight, Crystal, additional, Klumpp-Thomas, Carleen, additional, Thomas, Craig J., additional, Häupl, Björn, additional, Oellerich, Thomas, additional, Rae, Zachary, additional, Kelly, Michael C., additional, Ahn, Inhye E., additional, Sun, Clare, additional, Gaglione, Erika M., additional, Wilson, Wyndham H., additional, Wiestner, Adrian, additional, and Staudt, Louis M., additional

Published
2021
Full Text
View/download PDF

36. Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study

Author

Desai, Sanjal, primary, Mo, Clifton, additional, Gaglione, Erika M., additional, Yuan, Constance M., additional, Stetler-Stevenson, Maryalice, additional, Tian, Xin, additional, Maric, Irina, additional, Wake, Laura, additional, Farooqui, Mohammed Z., additional, Drinkwater, Dennis C., additional, Soto, Susan, additional, Valdez, Janet, additional, Hughes, Thomas E., additional, Nierman, Pia, additional, Lotter, Jennifer, additional, Marti, Gerald E., additional, Pleyer, Christopher, additional, Sun, Clare, additional, Superata, Jeanine, additional, Nichols, Cydney, additional, Herman, Sarah E. M., additional, Lindorfer, Margaret A., additional, Taylor, Ronald P., additional, Wiestner, Adrian, additional, and Ahn, Inhye E., additional

Published
2021
Full Text
View/download PDF

37. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

Author

Ahn, Inhye E., primary, Tian, Xin, additional, Ipe, David, additional, Cheng, Mei, additional, Albitar, Maher, additional, Tsao, L. Claire, additional, Zhang, Lei, additional, Ma, Wanlong, additional, Herman, Sarah E. M., additional, Gaglione, Erika M., additional, Soto, Susan, additional, Dean, James P., additional, and Wiestner, Adrian, additional

Published
2021
Full Text
View/download PDF

38. A phase II study of ibrutinib and short‐course fludarabine in previously untreated patients with chronic lymphocytic leukemia

Author

Pleyer, Christopher, primary, Tian, Xin, additional, Rampertaap, Shakuntala, additional, Mu, Rui, additional, Soto, Susan, additional, Superata, Jeanine, additional, Gaglione, Erika, additional, Sun, Clare, additional, Lotter, Jennifer, additional, Stetler‐Stevenson, Maryalice, additional, Yuan, Constance M., additional, Maric, Irina, additional, Pittaluga, Stefania, additional, Rosenzweig, Sergio, additional, Fleisher, Thomas, additional, Wiestner, Adrian, additional, and Ahn, Inhye E., additional

Published
2020
Full Text
View/download PDF

39. Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Author

Alsadhan, Anfal, primary, Cheung, Jean, additional, Gulrajani, Michael, additional, Gaglione, Erika M., additional, Nierman, Pia, additional, Hamdy, Ahmed, additional, Izumi, Raquel, additional, Bibikova, Elena, additional, Patel, Priti, additional, Sun, Clare, additional, Covey, Todd, additional, Herman, Sarah E.M., additional, and Wiestner, Adrian, additional

Published
2020
Full Text
View/download PDF

40. Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Author

Desai, Sanjal, primary, Drinkwater, Dennis, additional, Mo, Clifton Craig, additional, Farooqui, Mohammed ZH, additional, Soto, Susan, additional, Valdez, Janet, additional, Gaglione, Erika M, additional, Tian, Xin, additional, Nierman, Pia, additional, Lotter, Jennifer, additional, Marti, Gerald, additional, Nichols, Cydney, additional, Taneja, Alankrita, additional, Herman, Sarah E. M., additional, Maric, Irina, additional, Wake, Laura M, additional, Stetler-Stevenson, Maryalice, additional, Yuan, Constance M., additional, Hughes, Tom, additional, Lindorfer, Margaret A., additional, Taylor, Ronald P., additional, Wiestner, Adrian, additional, and Ahn, Inhye E, additional

Published
2019
Full Text
View/download PDF

44. Cytotoxicity of the CD3 × CD20–bispecific antibody epcoritamab in CLL is increased by concurrent BTK or Bcl-2 targeting

Author

Mhibik, Maissa, Gaglione, Erika, Eik, David, Herrick, John, Le, Janet, Ahn, Inhye E., Chiu, Christopher, Wielgos-Bonvallet, Monica, Hiemstra, Ida H, Breij, Esther CW, Chen, Jenny, Reilly, Edward B., Epling-Burnette, Pearlie K., Szafer-Glusman, Edith, Sun, Clare, and Wiestner, Adrian

Abstract

•Epcoritamab-mediated killing of CLL cells by autologous T cells correlates with the effector-to-target ratio but not CD20 expression.•Epcoritamab efficacy is increased by concurrent use of a BTKi or venetoclax, supporting combination therapy.

Published
2023
Full Text
View/download PDF

45. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient–derived xenografts

Author

Zhang, Deyi, Harris, Hailey M., Chen, Jonathan, Judy, Jen, James, Gabriella, Kelly, Aileen, McIntosh, Joel, Tenn-McClellan, Austin, Ambing, Eileen, Tan, Ying Siow, Lu, Hao, Gajewski, Stefan, Clifton, Matthew C., Yung, Stephanie, Robbins, Daniel W., Piroozia, Mehdi, Skånland, Sigrid S., Gaglione, Erika, Mhibik, Maissa, Underbayev, Chingiz, Ahn, Inhye E., Sun, Clare, Herman, Sarah E.M., Noviski, Mark, and Wiestner, Adrian

Abstract

Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have become a preferred CLL therapy. Disease progression on covalent BTK inhibitors is commonly associated with C481 mutations. Here, we investigated a targeted protein degrader, NRX-0492, that links a noncovalent BTK-binding domain to cereblon, an adaptor protein of the E3 ubiquitin ligase complex. NRX-0492 selectively catalyzes ubiquitylation and proteasomal degradation of BTK. In primary CLL cells, NRX-0492 induced rapid and sustained degradation of both wild-type and C481 mutant BTK at half maximal degradation concentration (DC50) of ≤0.2 nM and DC90of ≤0.5 nM, respectively. Sustained degrader activity was maintained for at least 24 hours after washout and was equally observed in high-risk (deletion 17p) and standard-risk (deletion 13q only) CLL subtypes. In in vitro testing against treatment-naïve CLL samples, NRX-0492 was as effective as ibrutinib at inhibiting BCR-mediated signaling, transcriptional programs, and chemokine secretion. In patient-derived xenografts, orally administered NRX-0492 induced BTK degradation and inhibited activation and proliferation of CLL cells in blood and spleen and remained efficacious against primary C481S mutant CLL cells collected from a patient progressing on ibrutinib. Oral bioavailability, >90% degradation of BTK at subnanomolar concentrations, and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degraders uniquely suitable for clinical translation, in particular as a strategy to overcome BTK inhibitor resistance. Clinical studies testing this approach have been initiated (NCT04830137, NCT05131022).

Published
2022
Full Text
View/download PDF

46. Select Antitumor Cytotoxic CD8 + T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Author

Baptista MJ, Baskar S, Gaglione EM, Keyvanfar K, Ahn IE, Wiestner A, and Sun C

Subjects
Adenine therapeutic use, Cells, Cultured, Humans, Adenine analogs & derivatives, CD8-Positive T-Lymphocytes immunology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Piperidines therapeutic use
Abstract

Purpose: In chronic lymphocytic leukemia (CLL), the T-cell receptor (TCR) repertoire is skewed and tumor-derived antigens are hypothesized as drivers of oligoclonal expansion. Ibrutinib, a standard treatment for CLL, inhibits not only Bruton tyrosine kinase of the B-cell receptor signaling pathway, but also IL2-inducible kinase of the TCR signaling pathway. T-cell polarization and activation are affected by ibrutinib, but it is unknown whether T cells contribute to clinical response., Experimental Design: High-throughput TCRβ sequencing was performed in 77 longitudinal samples from 26 patients with CLL treated with ibrutinib. TCRβ usage in CD4 + and CD8 + T cells and granzyme B expression were assessed by flow cytometric analysis. Antitumor cytotoxicity of T cells expanded with autologous CLL cells or with antigen-independent anti-CD3/CD28/CD137 beads was tested., Results: The clonality of the TCR repertoire increased at the time of response. With extended treatment, TCR clonality remained stable in patients with sustained remission and decreased in patients with disease progression. Expanded clonotypes were rarely shared between patients, indicating specificity for private antigens. Flow cytometry demonstrated a predominance of CD8 + cells among expanded clonotypes. Importantly, bulk T cells from responding patients were cytotoxic against autologous CLL cells in vitro and selective depletion of major expanded clonotypes reduced CLL cell killing., Conclusions: In patients with CLL, established T-cell responses directed against tumor are suppressed by disease and reactivated by ibrutinib. See related commentary by Zent, p. 4465 ., (©2021 American Association for Cancer Research.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results